99 results about "Vitiligo" patented technology

The application provides a tyrosinase-based transdermal delivery system for treating vitiligo, which is a core-shell structure, the core is tyrosinase, and the shell is a polymer shell layer. The application coats a polymer protective layer on the surface of the tyrosinase through in-situ polymerization reaction on the double bond of the tyrosinase, can effectively protect the activity of the tyrosinase and promote the transdermal delivery of the tyrosinase, and can control the targeted delivery of the tyrosinase nanogel to melanocytes in the deep part of the skin and hair follicle by adjusting the polymerization conditions of the polymer shell, so as to promote the in-situ synthesis of melanin. The transdermal delivery system of the application can also load active small molecules with anti-inflammatory function in the center of the tyrosinase, and the small molecules are released after being targeted and delivered to the inflammation area of vitiligo along with the tyrosinase nanogel, so as to relieve inflammation and protect melanocytes from damage.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The utility model provides a vitiligo novel target ultraviolet light therapeutic instrument, relates to skin treatment equipment technical field, including base, console, adjusting tube and phototherapy head, the console is installed on the base, the adjusting tube connects the console and the phototherapy head, the phototherapy head is provided with ultraviolet light source inside, and the ultraviolet light source is connected with the base. The front end of the phototherapy head is provided with an adjustable light shield, so that the problems that the irradiation range of the phototherapy head cannot be adjusted, a vitiligo disease area is not targeted, and surrounding normal skin can be irradiated in the use process of an existing ultraviolet light therapeutic apparatus can be solved; and the problems that the irradiation position and angle are not easy to fix when a traditional handheld phototherapy head is used for irradiation, and the phototherapy head is directly contacted with the skin due to mistaken touch are solved.

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The invention discloses observation of the curative effect of AKBA gel combined with narrow-spectrum UVB irradiation in treatment of leucoderma. The invention creatively discovers that the combined use of AKBA and phototherapy has a remarkable and better treatment effect on leucoderma for the first time, provides an effective drug combination strategy for treatment of leucoderma, and has a good clinical application prospect and important conversion significance in the technical field of research and development of leucoderma treatment drugs.

The invention discloses application of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor in preparation of a medicine for treating leucoderma, and belongs to the technical field of preparation of medicines for treating leucoderma. Through targeted inhibition of ACLY activity or specific knockout of ACLY in CD8 + T cells, abnormal activation of ACLY and secretion of killing effector molecules (Granzyme B, IFN-gamma, Perforin and the like) are inhibited, and infiltration of the CD8 + T cells to skin lesion parts is reduced, so that melanocytes are protected from immune injury, and the progress of vitiligo is blocked. The application is based on the abnormally high expression of ACLY in CD8 + T cells of vitiligo patients and the close association with disease activity, and a brand new targeted treatment thought and a medicine research and development direction are provided for vitiligo.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention discloses application of rifudine in preparation of a preparation for promoting cell melanin synthesis, and belongs to the technical field of special drugs. The invention provides a new application of rifudine, which can promote synthesis and secretion of melanin and expression of TYR, TRP-1 and TRP-2, provides a new functional component for enhancing synthesis of melanin in vivo and preparing products for treating vitiligo and the like, and has a wide application prospect in the fields of pharmaceutical preparations, cosmetics, care products, beauty products and the like.

The invention discloses a traditional Chinese medicine for treating leucoderma and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. Comprising medicine for oral administration, astragalus membranaceus, codonopsis pilosula, bighead atractylodes rhizome, rhizoma smilacis glabrae, Chinese yam, fructus psoraleae, angelica sinensis, buffalo horn shreds, dogwood, salvia miltiorrhiza, red paeony root, safflower carthamus, ligusticum wallichii, peach kernel, polygonum multiflorum, eclipta alba, white mulberry root-bark, divaricate saposhnikovia root, radix bupleuri, scutellaria baicalensis, curcuma aromatica, fingered citron, rhizoma cyperi, felwort, parched white peony root, tribulus terrestris, gardenia, radix angelicae and rhizoma typhonii. The external immersion liquid comprises fructus psoraleae, radix angelicae, cortex dictamni, radix polygoni multiflori, borax, rhizoma typhonii, semen cuscutae, flos carthami and white spirit. Through oral administration for regulating qi and blood, tonifying liver and kidney, dredging meridians and collaterals and consolidating root, external application for dredging local parts and promoting pigment, internal and external synergism and simultaneous treatment of both symptoms and root causes, the traditional Chinese medicine is especially suitable for middle-aged and elderly patients with qi and blood deficiency, deficiency of liver and kidney and qi stagnation and blood stasis type leucoderma.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The application discloses a chitosan-glycine-copper chelate and a preparation method and application thereof in treating leukoplakia and vitiligo. In the preparation, chitosan is first placed in an acid aqueous phase system, and is fully dissolved and forms a uniform transparent or translucent solution under stirring; then glycine is added, and the chitosan and the glycine are fully mixed under stirring to build an organic ligand environment containing multiple coordination groups; subsequently, a copper source is introduced to perform a chemical reaction, and finally the chitosan-glycine-copper chelate is obtained. The chitosan-glycine-copper chelate shows a strong promoting activity completely different from all other substances (including simple mixtures of components thereof), the chelate can continuously and significantly activate tyrosinase activity, and promote the formation of melanin, so that the purpose of treating leukoplakia and vitiligo is achieved.

The application discloses a compound morinda officinalis color-increasing liniment for treating vitiligo and a preparation method thereof, and particularly relates to the technical field of traditional Chinese medicine preparations, wherein the liniment is prepared from morinda officinalis, spilanthes acmella, giant knotweed, caesalpinia sappan, psoralea corylifolia, radix angelicae dahuricae and rhizoma smilacis glabrae as raw medicinal materials. The preparation method comprises the following steps: dynamic reflux extraction, percolation extraction, macroporous adsorption resin purification and preparation molding. Through the classification extraction and purification process, the photosensitive active ingredients are retained, and the photo-toxic impurities are effectively removed, so that the photo-toxicity is completely negative. The pharmacodynamic test shows that the liniment has a significant curative effect on vitiligo. The safety test shows that the liniment has no skin irritation and no allergenicity, and has excellent light safety. The quality research shows that the quality of the liniment is stable and controllable. The liniment has definite curative effect, high safety and stable quality, and has a good clinical application prospect.

The application discloses a mouse vitiligo induction model based on chronic stress factors, wherein different kinds of stress factors capable of triggering stress response of animals are applied to stimulate the mouse periodically within a certain time period, so as to prevent the mouse from producing habitual response to the stress source and to promote the mouse to become white and the tail epidermis to be flaky. The technical method is different from the existing vitiligo model method, is based on the mechanism of occurrence and development of vitiligo observed in the clinic, and promotes the mouse to truly develop the vitiligo phenomenon from the whole instead of simulating the disease evolution locally. Compared with the existing vitiligo promoting mechanism, the effect is more stable and the authenticity is higher. The technical method is based on the objective fact that the clinical vitiligo patients often combine anxiety and depression to design the stress factors, and considers that the stress factors and the occurrence and development of vitiligo may be inter-caused and viciously circulate, namely, the adverse life events as the stress factors cause the damage and dysfunction of the melanin synthesis system at the micro level and form the vitiligo change at the macro level.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention discloses a method for determining chemical components in a medicine for treating vitiligo, which relates to the technical field of medicine analysis, and is characterized in that ultra-high performance liquid chromatography-mass spectrometry is adopted to determine the content of chemical components in a Bailing tablet: psoralen, isopsoralen, astragaloside, quercetin, polysaccharide and amino acid. The determination method comprises the following steps: respectively injecting a reference solution and a test solution into a liquid chromatograph for determination to obtain a chromatogram, and calculating the content of paeoniflorin in a test sample by adopting an external standard method, chromatographic conditions of a chromatogram obtained by adopting a liquid chromatograph are as follows: octadecylsilane chemically bonded silica is taken as a filling agent. According to the method for determining the chemical components in the medicine for treating leucoderma, the established detection method is verified, and the result shows that the detection method is easy and convenient to operate, accurate in result, high in specificity and good in reproducibility.

1. Name of the product subject to this design: Laser Therapy Device (EXC-5001). 2. Purpose of this design: For use by medical institutions as an adjunct treatment for psoriasis and vitiligo. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

1. The name of the design product: excimer light therapy instrument (308nm). 2. The use of the design product: for the treatment of vitiligo. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

The utility model discloses a vitiligo treatment medicine smearing device which comprises a medicine bottle, an installation sleeve is arranged at the bottom end of the medicine bottle, a sealing mechanism is arranged in the installation sleeve, the sealing mechanism comprises a sealing sleeve, a sealing ring, a movable plate, a fixed sleeve and a limiting sleeve, the sealing sleeve is installed in the installation sleeve, the sealing ring is installed on the inner wall of the installation sleeve, and the movable plate is installed on the inner wall of the movable plate. The movable plate is attached to the top face of the sealing sleeve, the fixing sleeve is installed on the inner wall of the installation sleeve, the limiting sleeve is installed on the inner wall of the fixing sleeve, a medicine discharging mechanism is arranged on the movable plate, the sealing sleeve and a sealing ring are arranged in the installation sleeve to form a double-sealing structure of the sealing mechanism, and the movable plate and the sealing sleeve are tightly attached to be matched with multiple sets of sealing strips. Meanwhile, due to the combined design of a fixing sleeve and a limiting sleeve, the movement stability of the movable plate is guaranteed, the movable plate is prevented from shifting through the guiding effect of a limiting rod, the problem that in the prior art, sealing performance is insufficient is solved, and liquid medicine leakage and pollution are effectively avoided.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The application provides a composition containing salicin, a product and application thereof, and relates to the technical field of cosmetics. Specifically, the application provides application of salicin in promoting intracellular melanin synthesis, and it is first proved that salicin can promote intracellular melanin synthesis by promoting tyrosinase activity, thereby providing a new functional ingredient for enhancing intracellular melanin synthesis, and preparing a product for improving and treating white hair and vitiligo.

The invention relates to the technical field of skin detection equipment, and discloses an intelligent vitiligo detection device which comprises an intelligent detection and treatment equipment body, image acquisition equipment arranged on the intelligent detection and treatment equipment body and a hand placing and folding mechanism. The image acquisition equipment is fixed through a multi-angle adjusting frame, the angle can be flexibly adjusted to be attached to the skin, and uniform irradiation of ultraviolet light is guaranteed. The hand placing and folding mechanism comprises a lower folding plate which can be unfolded, through linkage of a telescopic rod and a spring, the device can adapt to hands of different sizes, and the universality of detection is improved. And the mechanism can also realize quick folding and storage towards the bottom of the equipment integrally through the matching of the positioning rod and the spring, and is compact in structure and convenient to store. The device further comprises an image processing system which can automatically segment a white spot area in the image, accurately calculate the area and the relative gray value of the white spot area and generate a quantitative analysis report. Through combination of structural innovation and intelligent analysis, accurate, objective and convenient detection of vitiligo conditions is realized.

The invention provides new application of an ATOX1 gene and ATOX1 protein, and belongs to the technical field of treatment of vitiligo diseases. The ATOX1 gene serving as a key gene of copper metabolism is disclosed for the first time, and melanin synthesis is promoted by activating the melanocyte copper metabolism process, so that the effect of resisting leucoderma is achieved. The ATOX1 gene and / or the ATOX1 protein can be used as a key biomarker in the vitiligo morbidity process, and a new target and a new molecular basis are provided for vitiligo research.

This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

The invention discloses an oral traditional Chinese medicine composition for treating psoriasis. The medicinal liquor is prepared from the following raw materials: prepared rehmannia root processed with yellow wine, fructus corni processed with yellow wine, radix morindae officinalis processed with salt water, herba cistanche processed with yellow wine, rhizoma acori graminei processed with ginger, radix polygalae processed with honey, poria cocos, schisandra chinensis processed with vinegar, radix aconiti lateralis processed with salt, cinnamon, fried ophiopogon root, lumbricus processed with wine, smoked plum pulp processed with vinegar, artemisia apiacea, pine needles of pine trees of more than five years, garden balsam stem, mint, 53-degree pure grains, mature vinegar, cicada slough, fried safflower, salted fructus psoraleae, poria with hostwood and agilawood. , vinegar-processed tortoise plastron, emblic leafflower fruit, raw cucumber and snow pear. The invention discloses an externally applied traditional Chinese medicine composition for treating psoriasis. The externally applied traditional Chinese medicine composition is prepared from the following raw material medicines: menthol, blumea oil, winter boiled oil, vaseline, purified water, radix sophorae flavescentis, saffron crocus, sand-fried semen strychni, fructus cnidii, coptis chinensis, radix angelicae, cortex dictamni and sulphur prepared from radish. The orally-taken traditional Chinese medicine has the effects of warming kidney to strengthen yang, permeating toxin and calming endogenous wind. The externally applied traditional Chinese medicine has the effects of clearing away heat and toxic materials, cooling blood and relieving itching. The traditional Chinese medicine composition is high in psoriasis cure rate, free of toxic and side effects and good in curative effect on neurodermatitis, eczema and leucoderma.

This invention relates to the use of C-176 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating vitiligo. The chemical structural formula of C-176 is as follows: This invention provides the use of C-176 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating vitiligo. Experiments have demonstrated that C-176 is effective in treating vitiligo, providing a new and effective treatment option for vitiligo.

The invention relates to an application of a receptor preference IL2 mutant or a PEGylated IL2 mutant thereof in preventing and / or treating vitiligo. The invention also relates to a method for using the IL2 mutant of receptor preference or the PEGylated IL2 mutant thereof in the application.

The utility model belongs to the technical field of vitiligo treatment, particularly relates to a phototherapy device for vitiligo treatment, and aims to solve the problem that in the prior art, when the phototherapy device is used traditionally, a light source is prone to irradiating the same position all the time, so that the use effect is affected, the following scheme is provided: the phototherapy device comprises a base, and a treatment table and a shading cover which are respectively arranged at the top of the base; the collecting box is fixedly mounted on one side of the treatment table; the sponge layer is fixedly mounted at the top of the treatment table; the display screen is fixedly mounted on the other side of the treatment table; the fixing mechanism is arranged at the top of the base and used for fixing a patient; the illuminating lamp adjusting mechanism is arranged at the top of the treatment table and used for adjusting the treatment position of the patient; the shading mechanism is arranged at the top of the base, the fixing mechanism comprises two supporting plates fixedly installed on one side of the shading cover, when the LED lamp is traditionally used, a light source can irradiate different positions, and the using effect is improved.

Vitiligo is a complex auto-immune skin disease resulting in melanocytes loss and skin depigmentation. Following-up on their previous work identifying mitochondrial DNA (mtDNA) in skin biopsies from some vitiligo patients, the inventors demonstrate here that melanocytes from non-lesional skin present elevated numbers of mtDNA variants associated with mtDNA release and can be classified as function of their number of mtDNA variants in low-variant (LV) and high-variant (HV) load. Vitiligo HV melanocytes display increased ROS production, reduced antioxidant capacity, elevated mitochondrial function and mtDNA release as compared to Vitiligo LV and healthy melanocytes. Sensing of mtDNA by the cGAS-STING pathway results in pro-inflammatory cytokine and chemokines production promoting the recruitment of cytotoxic CD8+ T cells. This cascade of events can be blocked with TBK1 inhibitors suggesting new therapeutic approaches for sub-population of vitiligo patients displaying HV mtDNA phenotype. The present invention relates to method for the treatment of vitiligo in a subject in need thereof comprising a step of administrating to the subject a therapeutically effective amount of TANK-binding kinase 1 (TBK1) inhibitor.

The invention discloses a method for analyzing the effect of active pharmaceutical ingredients between T cells and melanocytes in vitiligo. The method comprises the following steps: obtaining transcriptome data; performing differential gene analysis on the transcriptome data to obtain an analysis result; identifying a first gene associated with a disease; determining a second gene by using a machine learning algorithm; drawing a spatial distribution mode of a second gene in the leucoderma skin; carrying out molecular docking on the HSPA1A protein receptor and a small molecule drug ligand, and simulating and predicting a bioactive component for regulating a second gene in the drug; and evaluating the regulation effect of the bioactive components of the drug on the second gene expression pattern, endoplasmic reticulum stress and CD8 + T lymphocyte infiltration by using the animal model, and analyzing the effect of the active components of the drug between T cells and melanocytes. The method provided by the invention can be used for evaluating the effect of the active pharmaceutical ingredient in vitiligo treatment, and particularly determining the effect of the active pharmaceutical ingredient between T cells and melanin cells in vitiligo.

The invention relates to the technical field of medical instruments, in particular to a vitiligo precise treatment system based on image recognition. Comprising an image acquisition module, a real-time analysis module, a treatment planning module and an operation guiding module. And the image acquisition module is used for acquiring contrast image information of the skin area of the patient irradiated by the 308 emitting head and the wood lamp in real time. According to the invention, through the closed-loop design of image acquisition, analysis, planning and guidance, intelligent accurate control and visual guidance are provided for manual operation, so that the problems of laser divergence, energy attenuation, out-of-control dosage and high calculation power cost of non-contact irradiation are avoided; the device has the advantages that the device is simple in structure and convenient to use, the defects that a traditional contact pressing mode depends on medical care experience, operation is tired and accuracy is insufficient are overcome, the accuracy of manual control over an irradiation path by medical staff is greatly improved, the problems of repeated irradiation, missing irradiation and the like are solved, the physical load and cognitive pressure of the medical staff are remarkably relieved, and treatment accuracy, safety and operation efficiency are improved.